The Business of Dry Eye: 4 Steps to Boosting Practice Profitability with In-Office Treatments
Michael A. Farbowitz, MD highlights the financial challenges and time commitments associated with traditional surgeries like laser vision correction (LVC) and cataract procedures, emphasizing the relatively lower risk and liability of in-office DED procedures. The author describes the step-by-step process of screening patients for DED, educating them about the condition, and offering in-office treatments such as OptiLight, LipiFlow, and TearCare. The article emphasizes the profitability of these procedures, citing profit margins per treatment and the ability to attract a broader patient base. Farbowitz advocates for proactive screening of all patients for DED, even those without symptoms, and discusses the positive impact on overall practice revenue, patient satisfaction, and referrals.
Dry Eye Care is Whole Body Care
Addressing dry eye disease (DED) requires a comprehensive, multidisciplinary approach that goes beyond traditional medical treatments. Laura M. Periman, MD emphasizes the importance of considering the second section of the updated definition of DED, which includes “neurosensory compromise.” This refers to the role of the brain in regulating tear film composition based on constant signals and feedback it receives. The article highlights the interconnectedness of various factors, including stress, anxiety, depression, and sleep disturbances, in contributing to the dysfunction of the lacrimal functional unit and the loss of homeostasis in DED. The author suggests that a holistic approach to patient care, encompassing lifestyle changes, nutritional support, and mental health considerations, is imperative for successful management of DED.
Why Wait? Rethink Your Approach to DED Treatment
In this video, care doctors share their experiences and opinions on treating dry eye in clinical practice.
Watch Now
OptiLight Unlocks Possibilities for Dry Eye Patients and Practices
James Chelnis, MD, discusses the transformative impact of OptiLight by Lumenis, a light-based therapy for managing dry eyes. The technology has received de-novo FDA approval and is distinguished by its patented OPT™ technology, providing a real and evidence-based solution for DED. Over 5 years, more than 50 clinical studies involving 2,500 patients have been conducted, demonstrating significant improvement in dry eye signs. OptiLight is the only FDA-approved intense pulsed light for managing dry eye.
Tackling dry eye disease: a clinical approach to treatment
Dry eye disease is highly prevalent in the United States. It’s estimated that dry eye effects more than 22 million Americans and the number of new patients are expected to increase as the population ages. Mark Dlugoss, senior contributing editor of Ophthalmology 360, and Darryl White, MD, founder of Sky Vision Center is located in Westlake, Ohio, outline clinical points associated with this growing medical problem.
Related Content
